articleThe LancetSep 1, 2024GREEN OA

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

University of Chicago · Kanagawa Prefectural Hospital Organization · +16 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

219
total citations
FWCI
54.90
Percentile
100%
References
25
Citations per year

Authors

274

Topics & keywords

Keywords
  • Pembrolizumab
  • Medicine
  • Chemotherapy
  • Oncology
  • Stage (stratigraphy)
  • Internal medicine
  • Lung cancer
  • Adjuvant
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding